港股创新药继续调整

Group 1 - The Hong Kong innovative drug sector continues to adjust, with leading stocks collectively declining and the Hong Kong Stock Connect innovative drug ETF (520880) falling over 1% for four consecutive days, despite strong buying interest in the market [1] - The launch of the China Drug Price Registration System on December 2 is expected to benefit the global market development of innovative drugs [1] - Analysts believe that the trend of the innovative drug industry will remain unchanged by 2026, indicating potential for rebound after the current adjustments [1] Group 2 - Investment in innovative drugs can be primarily directed towards the Hong Kong Stock Connect innovative drug ETF (520880) and its off-market linked fund (025221), which have three major advantages in their underlying index [1] - As of November 30, the ETF has a scale of 2.142 billion yuan, with an average daily trading volume of 458 million yuan since its listing [1]